Test Selection Guide - Dorevitch
• Haematological oncology - Fusion probes for common haematological malignancies, e.g. t(9;22) bcr/abl - Multiple myeloma panel - CLL panel • Solid tumour oncology-Paraffin tissue studies - Neu - ALK ROS1 - Oligodendroglioma - Lymphoma Molecular Genetics Inherited Haematological Disorders • Alpha thalassaemia genetic testing
Download Test Selection Guide - Dorevitch
Information
Domain:
Source:
Link to this page:
Documents from same domain
Test Selection Guide - Dorevitch
www.dorevitch.com.auAcceptable Test Groupings Approved Abbreviations in Parenthesis Blood Gases • PO2 • PCO2 • pH • HCO3 • base excess • O2 saturation Electrolytes (E)
Breast and Ovarian Cancer - Dorevitch Pathology
www.dorevitch.com.auFOR MEDICAL SPECIALISTS Breast and Ovarian Cancer Guide for Genetic Testing
SWAB GUIDE - Dorevitch
www.dorevitch.com.auPATHOGENS SITE SWAB DESCRIPTION FEATURES INSTRUCTIONS NOT SUITABLE FOR Bacteria & Yeasts For Microscopy, Culture and Sensitivity Any Blue top Regular Tip General Mini Tip Plastic Swab
Generation® NIPT Genetic Counselling Service - …
www.dorevitch.com.auGeneration® NIPT Genetic Counselling Service Dorevitch Pathology and their genetics laboratory, Genomic Diagnostics, are pleased to announce access
COLLECTION INSTRUCTIONS - Dorevitch
www.dorevitch.com.auReferred Specimens Blood/ Fluid/Tissue Sterile Container Non-rebateable test. Refer to non-rebateable price list. Patient payment consent required. 17 Ketosteroids (Urine)€ Biochemistry 24hr urine collection/Urine collection bottle with no preservative No preservative (plain). Please note start date / time and finish date / time on request form.
Related documents
People with Learning Disabilities in Scotland: 2017 Health ...
www.healthscotland.scotdemographic profile. The changes include increased longevity and changing patterns of morbidity and mortality. The past decades have seen a similar increase in life expectancy as those found in the general population, except for those with Down syndrome, epilepsy or multiple disabilities (Hosking et al., 2016; Kelly & Kelly, 2012; Coppus, 2013).
NSSG Chemotherapy Protocol
nssg.oxford-haematology.org.ukDose adjustment for Haematological Toxicity Indication Counts Modification Chronic phase CML (400mg) ANC < 1.0 x 109/L and/or Plt < 50 x 109/L 1. Stop Imatinib until ANC ≥ 1.5 x 10 9/L and Plt ≥ 75 x 10/L 2. Resume treatment at previous dose 3. Recurrence of ANC < 1.0 x 10 9/L and/or Plt < 50 x 10 /L,
NSSG Chemotherapy Protocol
nssg.oxford-haematology.org.ukDose Reduction - Haematological Count Modification Plt < 50 x 109/L or ANC < 0.5 x 109/L or Hb < 80g/L in PV Stop ruxolitinib. Once recovered above these levels, resume ruxolitinib 5mg PO twice a day and gradually increased based on careful monitoring of FBC including white blood cell count differential. Plt < 100 x 109/L or
2019 update of the EULAR recommendations for the ...
ard.bmj.comfor cutaneous, neuropsychiatric, haematological and renal disease. Patients with SLE should be assessed for their antiphospholipid antibody status, infectious and cardiovascular diseases risk profile and preventative strategies be tailored accordingly. The updated recommendations provide physicians and patients with
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euAdditive haematological adverse reactions may be expected if cladribine is administered prior to or concomitantly with other substances that affectthe haematological profile(see section4.5). Lymphocyte counts must be determined before initiating MAVENCLAD in year1, before initiating MAVENCLAD in year2,
Lung Ultrasound - European Society of Cardiology
www.escardio.orgHead, Cardiovascular Emergencies and Onco-Haematological Complications Laboratory of Standard and Advanced Echocardiography Federico II University Hospital Vice President, EACVI ... The association of A profile with venous thrombosis (venous scan) favours the diagnosis of pulmonary embolism 81% sensitivity 99% specificity.
NCCP Chemotherapy Regimen Modified FOLFOX-6 Therapy …
www.hse.ieHaematological: Table 2. Dose Modifications for Haematological Toxicity Prior to a Cycles (DAY 1) TOXICITY Dose Level for Subsequent Cycles Grade ANC (x 109/L) Oxaliplatin Fluorouracil If ANC< 1.5 1on Day 1 of cycle, hold treatment, weekly FBC, maximum of 4 weeks ANC ≥ 1.5 within 4 weeks, proceed with treatment at the dose level